Dermal EZH2 simultaneously orchestrates Wnt/β-catenin signaling dependent dermal differentiation and retinoic acid signaling dependent epidermal proliferation during murine skin development

Venkata Thulabandu¹, Timothy Nehila¹, James W. Ferguson¹, Radhika P. Atit¹,²,³*

¹Dept. of Biology, Case Western Reserve University, Cleveland, Ohio, USA, ²Dept. of Genetics and Genome Sciences, ³Dept. of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA.
*Corresponding author: rpa5@case.edu. ORCID: 0000-0002-3492-6552

Abstract

Tissue development requires complex interactions between signaling factors, transcription factors, and epigenetic regulators. These complex interactions are tightly regulated to balance proliferation and differentiation of dermal fibroblasts and epidermal keratinocytes during skin development, but how this regulation is achieved is unclear. We found that Polycomb Repressive Complex 2 (PRC2), a key epigenetic regulator, is present throughout dermal development and is required for differentiation of murine dermal fibroblasts progenitors and for cell-cell communication to the overlying epidermis, two processes that are poorly understood during skin development. We found dermal Ezh2, the catalytic component of PRC2, is required to spatially restrict Wnt/β-catenin signaling to the sub-ectodermal cells fated to become dermal fibroblast progenitors. We also found dermal Ezh2 ablation results in dermal fibroblast progenitor differentiation into ectopic reticular dermal cells and delayed secondary hair follicle initiation. Additionally, dermal Ezh2 deletion leads to elevated proliferation of epidermal basal keratinocytes resulting in hyperplasia of all epidermal layers. Transient elevation in retinoic acid (RA) signaling in wild-type mice leads to epidermal hyperplasia and small molecule inhibition of RA signaling can rescue epidermal hyperplasia in dermal Ezh2 mutants. Together, our study reveals that PRC2 acts as a rheostat to control the levels of Wnt/β-catenin and RA signaling to respectively impact fibroblast differentiation cell autonomously and keratinocyte proliferation non-cell autonomously.

Introduction

Differentiation of multipotent progenitors towards terminal fates is an essential component of development. Transcription factors aid in the execution of cell fate selection intrinsically by controlling the expression of fate-specific genes¹-⁴. Cell-cell communication can also affect differentiation of a target cell through extrinsic juxtracrine and paracrine factors⁵-⁷. The presence of both intrinsic transcription factors and cell-cell communication through extrinsic factors is
evident and indispensable in cell fate selection during development of many organs including skin\textsuperscript{6–8}. However, the mechanisms that control the temporal and spatial coordination of intrinsic and extrinsic factors during cell differentiation and cell-cell communication are not clearly understood. Although in vitro studies have identified that epigenetic complexes may regulate coordination of cell signaling of multiple pathways\textsuperscript{9,10}, it remains unclear as to what extent and how epigenetic complexes orchestrate coordination of cellular heterogeneity and cell-cell communication in developing tissues. Here, we use the murine skin as a model to understand the role of developmental epigenetic regulators in generating dermal fibroblast heterogeneity and dermal-epidermal communication.

The murine dermis consists of dermal fibroblasts that undergo differentiation while reciprocally signaling overlying epidermal keratinocytes to induce appendages\textsuperscript{7,11,12}. Murine dermal fibroblasts and its interaction with the epidermal keratinocytes serve as an excellent model system to address the question of whether PRC2 can coordinate cellular differentiation both cell autonomously through intrinsic factors and non-cell autonomously through inter-cellular communication. The differentiation of dermal fibroblasts and the reciprocal signaling to the epidermal keratinocytes are integral to skin patterning, development of appendages\textsuperscript{7,12} and healing\textsuperscript{13,14}. In mice, by embryonic day (E) 9.5, the dermal fibroblast (DF) precursors migrate from somites to sub-epidermal locations and differentiate into DF progenitors between E11.5 and E13.5\textsuperscript{7,15–17}. The DF progenitors then differentiate into papillary fibroblasts progenitors (PPs), reticular fibroblasts progenitors (RPs), and hair-forming dermal papilla fibroblasts (DPs), with distinct gene expression profiles as early as E14.5\textsuperscript{17,18} (Fig.1A). PPs, differentiate into papillary fibroblasts, and DPs which are crucial for communicating to the epidermis and stimulating hair follicle morphogenesis and cycling\textsuperscript{18,19}. RPs differentiate into dermal white adipose tissue (DWAT), which aids in thermal insulation\textsuperscript{18,20}, and reticular fibroblasts, which secrete dense collagen fibers to provide elasticity to the skin\textsuperscript{21}. It is unknown whether PRC2 controls dermal fibroblasts heterogeneity and impacts dermal signaling to the epidermis during skin development.

Polycomb group proteins (PcG) are one of the most well-studied epigenetic complexes that regulate cell differentiation through mediation of both intrinsic and extrinsic developmental signals\textsuperscript{22–24}. Polycomb Repressive Complex2 (PRC2) is a PcG complex consisting of three core proteins: SUZ12, EED and EZH2. EZH2 is the catalytic component that mediates the trimethylation of Lysine27 on Histone 3 (H3K27me3) resulting in gene silencing. Deleting Ezh2 in epidermal basal keratinocytes leads to derepression of multiple late epidermal differentiation genes resulting in epidermal hyperplasia and precocious barrier acquisition\textsuperscript{25}. Ablation of both Ezh1 and Ezh2 in epidermal basal keratinocytes leads to ectopic differentiation of keratinocytes into Merkel cells mediated by an increase in Sox2 expression\textsuperscript{26,27}. Deleting Ezh2 in cranial mesenchyme leads to upregulation of anti-osteogenic genes resulting in reduction of the size of skull bones\textsuperscript{28–30}. These studies emphasize the ability of PcG to regulate differentiation cell autonomously. Besides, a previous study lends support to the non-cell autonomous regulation of PcG\textsuperscript{31}. Ablation of E(z), the drosophila homologue of EZH1/2, in somatic gonad cells leads to somatic cell marker expression in drosophila germ cells in a non-cell autonomous manner\textsuperscript{31}. These studies have demonstrated a requirement of PRC2 in regulating various intrinsic or extrinsic factors required for cell differentiation across different tissues. However, the ability of whether PRC2 coordinates various intrinsic and extrinsic factors in multipotential progenitor cells to simultaneously impact cell differentiation and cell-cell communication is not clear.

Multiple signaling pathways regulate development of DF progenitors in vivo during cell
fate selection and differentiation. Many of the key transcription factors and signaling factors involved in DF progenitor development are regulated by PRC2 in other cell types\textsuperscript{23,24,29}, and single gene deletions have not yielded strong dermal phenotypes. However, Wnt/β-catenin signaling regulates several transcription factors expressed between E9.5 and E11.5, such as En1, Msx1, Msx2, Lef1, Twist1, Twist2 and is required for dermal fibroblast cell fate determination\textsuperscript{7,15,16,32,33}. Ablation or overexpression of β-catenin in DF precursors shows that canonical Wnt signaling is necessary and sufficient for specification of DF progenitors fate, respectively\textsuperscript{7,15,16,32}. Wnt signaling expressing DF progenitors give rise to dermal condensate cells and PPs that are precursors to DP cells and are required for hair follicle initiation in embryonic mouse skin\textsuperscript{34,35}. Wnt and BMP signaling are required to maintain DP's ability to induce hair follicles\textsuperscript{36}. RA signaling in DF progenitors is required to specify dermal condensate cells as shown by dermal fibroblasts restricted deletion of RA inhibitor, Cyp26b1\textsuperscript{37}. Although, some of the signals governing the differentiation of DF precursors to DF progenitors have been identified, the mechanisms required to coordinate the spatio-temporal differentiation DF progenitors into PP, RP and DP lineages remain unidentified. However, whether PRC2 orchestrates these signals and factors in dermal fibroblasts is unknown.

Here, we tested the role of PRC2 in embryonic dermal development and dermal-epidermal signaling, via cell-type and temporal-specific deletion of Ezh2 in mouse DF precursors \textit{in vivo}. Here, we found that dermal Ezh2 is required for differentiation of DF precursor to DF progenitors and RPs by spatially restricting Wnt/β-catenin signaling and but not for generating the other lineages. Dermal PRC2 is required for secondary hair follicle formation and dispensable for primary guard hair follicle initiation. We found that deletion of dermal Ezh2 aberrantly enhances RA signaling and causes epidermal hyperplasia by elevating proliferation. We further demonstrate the molecular mechanism of this specific action of dermal Ezh2. We show that RA signaling is a key driver and transient activation of RA signaling recapitulates the phenotype and inhibition of RA signaling rescues the epidermal hyperplasia \textit{in vivo}. Thus, dermal PRC2 directed downregulation of the RA pathway is critical for the timely activation of the epidermal proliferation and inhibition of differentiation. Altogether, these results demonstrate new and unexpected roles for dermal PRC2 to cell autonomously regulate the stepwise differentiation of dermal fibroblast cell types and non-cell autonomously regulate epidermal proliferation by maintaining critical levels of dermal Wnt/β-catenin and RA signaling.

**Materials and Methods**

**Mice**

The following mice were utilized for this project: PdgfraCreER (JAX stock #018280)\textsuperscript{38}, Rosa26-lacZ reporter (JAX stock #003309)\textsuperscript{39}, Ezh2 floxed (Ezh2\textsuperscript{fl/ff}) (JAX stock #022616)\textsuperscript{40}, Axin2\textsuperscript{lacZ} reporter (JAX stock #009120)\textsuperscript{41,42}, and RARE-hsp68-LacZ reporter (JAX stock # 008477)\textsuperscript{43}. Each of these genotypes was maintained in a mixed genetic background. The males and females were time mated and the vaginal plugs were checked daily. A plug is assigned E0.5. Tamoxifen (Sigma Aldrich T5648) dissolved at 10mg/ml in corn oil was gavaged to mice at 25μg/g of body weight on E8.5 and E9.5. For the rescue experiments, BMS453\textsuperscript{44–46} (Cayman Chemical Company 19076) dissolved at 3.5μg/μl in DMSO and diluted in corn oil was gavaged to mice at 3.5μg/g of body weight on E8.5, E9.5, E11.5, E13.5, and E15.5. To the wild type mice, at-retinoic acid (Sigma Aldrich R2625) dissolved at 100mg/ml in DMSO and diluted in peanut oil was gavaged to mice.
at 100μg/g of body weight on E9.5 and E10.5. For each experiment a minimum of 3 controls and 3 mutants were utilized. Case Western Reserve University Institutional Animal Care and Use Committee approved all animal procedures in accordance with AVMA guidelines (Protocol 2013–0156, Animal Welfare Assurance No. A3145-01).

**Histology and stains**

Cryosectioning: (i) For cryo embedding, we followed the protocol previously published. Once embedded, the embryos were cryo-sectioned at 10 μm and 20 μm thickness for LACZ staining in the transverse plane. (ii) For paraffin embedding, the embryos were fixed in 4% paraformaldehyde overnight, equilibrated with 70% ethanol overnight at 4°C, and processed for paraffin embedding. These embryos were then sectioned onto charged slides at 10 μm thickness.

Histological Stains: For β-Galactosidase detection, the cryo-sectioned slides were dried for 15 mins, fixed with 4% paraformaldehyde for 5 mins and stained with X-gal compound (Amresco 0428) dissolved at 1mg/ml for 3-6hrs at 37°C as previously described. For Masson’s Trichrome staining, paraffin sectioned slides were stained with Weigert Iron Hematoxylin, Biebrich Scarlet-Acid Fuchsin Solution and Aniline Blue Solution using the standard protocol. For Alkaline phosphatase staining, cryosections were rinsed in PBS for 10 mins, fixed ice-cold Acetone on ice for 10 mins, then washed in NTMT (100mM Tris, pH9.4, 100mM NaCl, 60mM MgCl2, 0.02% Tween-20) for 10 mins at RT. Embryos were stained in 20μl/ml NBT/BCIP (Roche 11681451001) in the dark for 10 mins at RT. Slides were washed in PBS and mounted with aqueous mounting medium.

Immunostaining: For immunostaining, the slides were dried for 15 mins, washed in PBS, blocked with buffer (PBS + 1% BSA + 0.1% Tween20/Triton-X-100) with 10% goat or donkey serum for 1hr. Slides were incubated with primary antibodies overnight. Species-specific fluorescent or biotinylated secondary antibodies were incubated for 1hr to stain the slides. The following primary antibodies were utilized: rabbit anti-Twist2 (1:200; Abcam66031), goat anti-PDGFRα (1:150; R&D AF1062), rabbit anti-H3K27me3 (1:1000; Cell Signaling C36B11), rabbit anti-Lef1 (1:100; Cell Signaling C12A5), goat anti-Dlk1 (1:50; R&D AF1144), goat anti-Lrig1 (1:100; R&D AF3688), rabbit anti-TCF4 (1:100; Cell Signaling C48H11), rabbit anti-TCF1 (1:300; Cell Signaling C63D9), rabbit anti-K14 (1:2000; Covance PRB-155P), rabbit anti-K10 (1:500; Covance PRB-159P), rabbit anti-Filaggrin (1:500; Covance PRB-417P), and rabbit anti-RARγ (1:1000; Cell Signaling D3A4).

The EdU staining was implemented using the Click-iT Plus EdU kit (Thermo Fisher Scientific, C10639). The standard protocol suggested by the manufacturer was implemented.

Species-specific secondary antibodies Goat anti-Rabbit IgG Alexa 594 (1:800, Life Technologies, A11012) and Donkey anti-Rabbit IgG Alexa 594 (1:500, Life Technologies, A21207), Donkey anti-Rabbit IgG Alexa 488 (1:800, Life Technologies, A21208), Donkey anti-rat IgG Alexa 488 (1:500, A21208). The TSA-Kit secondary antibody system (Akoya biosciences, NEL763E001KT) was utilized with Lef1 immunostaining.

Images were taken on Olympus BX60 microscope with the Olympus DP70 digital camera using DC controller software. Confocal images were captured using Leica TCS SP8 (Leica Biosystems) using Application Suite X software (Leica Biosystems). Images were processed in Adobe Photoshop (www.adobe.com), Fiji/ImageJ, and CellProfiler™.
Barrier Assay: The embryos at E16 and E17.5 were equilibrated with a graded series of methanol and stained in 0.1% toluidine blue (Sigma-Aldrich T3260). The embryos were then washed in 1XPBS for 24hrs before recording the pictures.

Tissue harvesting and RT-qPCR

Ezh2<sup>fl/fl</sup> (control) and PdgfraCreER; Ezh2<sup>fl/fl</sup> (mutant) were used to harvest skin for gene expression analyses. For the embryos staged between E10.5 and E12.5, the dorsal halves of the bodies devoid of internal organs (carcass) were harvested. And for the embryos staged between E13.5 and E17.5, the dorsal skin was collected.

Fluorescence Activated Cell Sorting (FACS): Just for flow sorting experiment, PdgfraCreER; Rosa26<sup>-tdtomato</sup>; Ezh2<sup>fl/+</sup> (heterozygous control) and PdgfraCreER; Rosa26<sup>-tdtomato</sup>; Ezh2<sup>fl/fl</sup> (mutant) were used in place of aforementioned genotypes. The E10.5 tissue was collected directly into 0.25% Trypsin-EDTA (Thermo Fisher Scientific 25200056), minced, and homogenized for 4 mins at 37°C. The homogenized tissue was strained with 40μm filters (Fisher Scientific 22363547) and flow sorted into dermal (PdgfraCreER; Rosa26<sup>-tdtomato</sup> positive) and epidermal (negative) fractions using FACS-ARIA-II (P65011000099) with an 85μm nozzle. Doublets and dead cells were excluded based on forward scatter, side scatter and DAPI (0.2 mg/ml) fluorescence.

Once the select tissue/cells were collected, RNA was isolated using RNeasy MinElute cleanup kit (Qiagen 74204) with DNase treatment (Qiagen 79254), and mRNA concentration was determined using Nanodrop (ND-8000-GL). Then the mRNA was converted to cDNA using the High Capacity RNA-to-cDNA Reverse Transcription Kit (Life Technologies, 4387406).

Relative quantity of mRNA expressed was determined by using 4ng of cDNA on a StepOnePlus Real-Time PCR System (Life Technologies). Commercially available Taqman probes from Invitrogen were utilized: Ezh2- Mm00468460_m1, Cyp26b1- Mm00558507_m1, Twist2- Mm00492147_m1, Lef1- Mm00550265_m1, Twist1- Mm00442036_m1, Axin2- Mm00443610_m1, Suz12- Mm01304152_m1, and EED- Mm00469660_m1 to implement q-PCR. CT values obtained were normalized to β-actin (Invitrogen 4352663) to obtain ΔCT values. Then, the ΔCT values were normalized to the average ΔCT values of the controls to obtain ΔΔCT values and relative mRNA levels<sup>49</sup>.

Histomorphometrics and automated quantification of protein expression in cells:

Dermal thickness: Photos of the Masson’s Trichrome stained tissue were loaded to Fiji<sup>47</sup>. Using the line tool, a vertical line was drawn from the base of the epidermis (i) until the start of panniculus carnosus if present in the field (ii) until the end of the region with dense collagen staining if the panniculus carnosus was absent in the field. Lines were drawn at 5 fixed points in the field and measured for their length. The average of these 5 lengths represent the dermal thickness of the field.

Hair follicle staging: The hair follicles were staged as previously published<sup>50</sup>.

Epidermal area: The Hematoxylin and Eosin stained photos were loaded onto Fiji<sup>47</sup>. Using a freeform line tool, a box was drawn around the epidermis and the area (μm<sup>2</sup>) of the box was obtained.
H3K27me3 immunostaining: Images were acquired on the Olympus BX-60 with DP72 camera. The first 4 layers of the dermis was manually cropped out of the photo using the Adobe Photoshop freeform pen tool. Then the resultant photo was manually counted for percent H3K27me3+ cells.

TWIST2+ cells: Images were captured by Olympus BX-60 with DP72 camera at 20X. Using the freeform pen tool in Adobe Photoshop, three parallel lines were drawn to separate the epidermis, the first 6 layers of dermis, and the second 9 layers of dermis. Percent of cells that are TWIST2+ were manually counted in every region.

LEF1+ cells: Images were captured by Leica TCS SP8 gated STED 3X at 40X. Using the freeform pen tool in Adobe Photoshop, three parallel lines were drawn to crop the epidermis, the first 6 layers of dermis, and the underlying 9 layers of dermis into separate files. Using CellProfiler™, we used these photos to count LEF1+ cells: (i) The red and blue channels were split (ii) Each channel was smoothened by Gaussian filter with automatic filter size (iii) the uneven illumination in each photo was calculated with a 60 block size and corrected (iii) The noise was reduced in blue channels (Size:7, Distance:11, Cut-off distance: 0.065) and red channels (Size:7, Distance:11, Cut-off distance: 0.09) using ‘ReduceNoise’ function (iv) The number of red and blue objects were identified with adaptive Otsu three-class thresholding with an object diameter between 5 and 40.

Axin-LacZ and Rare-LacZ staining: The DAPI fluorescence and LacZ staining in transmitted light were captured by Leica TCS SP8 gated STED 3X at 40X. The LacZ (transmitted light) channel was inverted and converted (pseudo-colored) to Red by default CellProfiler™ settings. The pseudo colored photo was then cropped using the freeform pen tool in Adobe Photoshop to separate the epidermis, the first 6 layers of dermis and the underlying 9 layers of dermis into separate files by drawing 3 parallel lines. Then these photos were used to count the DAPI and LacZ+ cells present in them. In order to do that, (i) the cropped photos were split into separate channels (ii) the DAPI and LacZ channels were both smoothened with a Gaussian diameter of 3 and rescaled the intensity to full (iii) Then DAPI objects were identified by adaptive Otsu three-class thresholding with an object diameter between 4 and 40 (iv) The LacZ objects were identified by manual thresholding of 0.35 and segmented by watershed method with default settings. (v) The DAPI objects that did not have 35% of their area overlapped with LacZ objects were masked (vi) The number of unmasked DAPI objects and the total DAPI objects were noted in a file.

DLK+ and LRIG1+ cells: The merged photos of DAPI and red channel were loaded to Fiji. The approximate size of a box that can enclose four layers of the dermis was determined by studying multiple photos. For each photo, 5 ‘region of interest’ files were created: 1 just with the epidermis and 4 non-overlapping boxes splitting the first 16 layers of the dermis. After creating these files, the fluorescence intensity in each region of interest was measured against the background. Then to count the number of cells in each region, the merged photo was manually loaded on to Fiji and (i) Splitted into RGB channels and the blue channel is selected (ii) Gaussian smoothed with a radius of 1 (iii) Thresholding of ‘Dark background’ is implemented with automatic settings (iv) segmented with watershed (v) The number of DAPI cells were identified by analyzing the particles with a size between 0.1 and infinity, and circularity between 0 and 1. Using the fluorescence intensity and number of DAPI cells in each region, the corrected fluorescence intensity was determined.

TCF1+ and TCF4+ cells: The brightfield photos were manually cropped to consist of just the dermis (devoid of hair follicles and other tissues). Color deconvolution plugin in Fiji was used to separate hematoxylin and DAB staining and each of the channels were saved in separate files. Then
CellProfiler™ was used to count the number of hematoxylin and DAB cells by doing the following on both the files (i) The image was inverted to brighten the dark spots and vice versa (ii) The image was transformed to grayscale (iii) the noise was reduced in both DAB (Size: 7, Distance: 11, Cut-off distance: 0.075) and hematoxylin (Size: 7, Distance: 11, Cut-off distance: 0.05) channels using ‘ReduceNoise’ function (iv) The number of DAB+ and Hematoxylin+ objects were identified with adaptive Otsu three class thresholding with an object diameter for DAB between 5 and 30 and for hematoxylin between 5 and 40.

Basal and suprabasal cell counts: The merged photos of DAPI and K14 staining were loaded to Adobe Photoshop. The cells that expressed K14 (basal cells) and the cells on top of K14+ cells (suprabasal cells) were manually counted.

EdU staining: At E10.5, images were taken on Olympus BX60 microscope with the Olympus DP70 digital camera. Using the freeform pen tool in Adobe Photoshop, 2 parallel lines were drawn to divide the epidermis and from the first 4 layers of dermis into separate files. And then the percent of Edu+ cells were manually counted.

Statistics:
All graphs were generated using Prism 6 (GraphPad Software: https://www.graphpad.com/scientific-software/prism/). All the statistical analyses were carried out in Microsoft excel using the Student’s t-test function using an unpaired, two-tail, with unequal variance. The p-values for statistical tests in all figures are represented as: * = P < 0.05, **= P < 0.01 and ***= P < 0.001.

Results

Ezh2 is active throughout murine dermal development and can be efficiently ablated in dorsal dermal fibroblast precursors using PDGFRαCreER

To identify the spatio-temporal timing of PRC2 activity during dermal development, we queried PRC2-mediated H3K27me3 activity by immunostaining at various stages in mouse embryonic skin development (Fig.1A). We observed persistent expression of H3K27me3 from as early as E11.5 through E17.5 in the differentiating DFs (Fig.1B). This indicates that EZH2 is active throughout dermal development as the DF progenitors begin differentiating and signaling to the epidermis between E11.5 and E13.5.

To address the role of Ezh2 in regulating DF differentiation, we used tamoxifen-inducible pan-mesenchymal PDGFRαCreER to conditionally delete Ezh2 and activate Rosa26 β-galactosidase (R26R) in DF precursors and broadly in the dorsal mesenchyme at E8.5 and E9.5, (E8.5-DermEzh2) (Fig.1A, 1C). As early as E10.5, we observed a 3.19-fold decrease in Ezh2 mRNA in DF precursors in E8.5-DermEzh2 as compared to Ezh2 heterozygous controls (Fig. S1A). The activity of PDGFRαCreER-mediated recombination of R26R is confined to the dorsal DF progenitors at E13.5 and absent in the epidermis as can be seen from β-gal staining (Fig.1D, 1E). We visualized cells with Ezh2 methyltransferase activity, by determining the number of H3K27me3 expressing DF precursors and progenitors. We found a 85% decrease of H3K27me3+ DF precursor cells in E8.5-DermEzh2 mutants at E10.5 (Fig.1F, G, H) and 88% decrease in DF
progenitors at E13.5 (Fig.S1B, C) suggesting that Ezh2 deletion in DF precursors is robust with our gavage regimen with PDGFRαCreER preceding DF differentiation.

**Ezh2 deletion leads to upregulation of Wnt/β-catenin signaling and expansion of dermal fibroblast progenitors**

Upon confirming deletion of Ezh2 in DF precursors, we next sought to determine the effect of Ezh2 deletion on DF precursor differentiation into DF progenitors and the signals underlying dermal fibroblast fate selection (Fig. 1A, 2A’, 2A’’). The expression domain of a pan-mesenchymal marker, PDGFRα, at E13.5 was comparable between control and E8.5-DermEzh2 suggesting that cells retained their mesenchymal identity (Fig. 2B, C)18. We next sought to determine if DF precursor differentiation is altered in E8.5-DermEzh2 mutants. We examined the protein expression of DF progenitor markers, TWIST2 (DERMO1) and LEF1, at E12.5.7,15,16,32. Compared to the control, the expression domain of TWIST2 and LEF1 proteins was expanded with an 84% increase in TWIST2+ cells and 40% increase in LEF1+ cells in the deeper layers of the E8.5-DermEzh2 dorsal mesenchyme (Fig. 2E-J). DF progenitor cell density and cell proliferation at E12.5; and dermal thickness at E17.5 (Fig. S2A) were not significantly different between controls and the E8.5-DermEzh2 mutants. This indicates that dermal-Ezh2 deletion leads to an ectopic acquisition of deeper dorsal mesenchymal cells to DF progenitor identity.

Because Wnt/β-catenin signaling is known to be involved in cell fate decisions and both TWIST2 and LEF1 are among its targets, we further investigated whether there was an upregulation of canonical Wnt/β-catenin signaling7,16,32. We utilized the Wnt/β-catenin signaling reporter, Axin2-LacZ, to look for changes in domains of Wnt signaling following loss of Ezh2.41,42. β-gal staining revealed an increase in the size of the domain of Axin2-LacZ expression in E8.5-DermEzh2 at E12.5. We identified a 144% increase in ectopic Axin2-LacZ+ cells in the deeper layers of the E8.5-DermEzh2 dorsal mesenchyme indicating an expansion of elevated canonical Wnt/β-catenin signaling (Figure 2K-M). Thus, the increase in TWIST2+ and LEF1+ DF progenitors results from an expansion of Wnt/β-catenin signaling domain mediated differentiation of dorsal mesenchymal cells underlying the dermis. These data reveal a new role for dermal PRC2 in spatially restricting Wnt signaling activity and its target genes to DF progenitors in vivo during dermal specification window.

**Ablation of dermal Ezh2 promotes differentiation of dermal fibroblast progenitors towards reticular progenitors and delays secondary dermal papilla formation**

As early as E14.5, dermal fibroblast progenitors differentiate into its derivates such as PPs, RPs and DPs as seen by their distinct marker expression17,18 (Fig.1A). Many known signaling molecules and transcription factors that regulate dermal differentiation are targets of Wnt/β-catenin signaling18,35,51,52. From E12.5 to E14.5, the epidermis expresses canonical Wnt ligands which are required for Wnt/β-catenin signaling in DF progenitors and subsequently the Wnt-dependent differentiation of DF progenitors into PPS and DPs7,12.

Wnt/β-catenin signaling is upregulated in E8.5-DermEzh2 at E12.5 and persists until E13.5 as indicated by the relative quantity of Lef1 and Axin2 mRNA expression in whole skin (Fig. S2F, G, TableS1). The markers of PPs, RPs and DPs are known targets of Wnt/β-catenin signaling7,33 (Fig.1A). So, we next examined the effect of increased Wnt/β-catenin signaling, due to Ezh2 ablation, on the differentiation of DF Progenitors (Fig.1A). LRIG1 and TCF1 are markers of papillary progenitors, and DLK1 and TCF4 are markers of reticular progenitors17,18.
Histomorphometric analysis revealed that protein expression domain of LRIG1 and DLK1 was comparable between E16.5 controls and E8.5-Derm<sup>Ezh2</sup> in the dermis (Fig S3A-G). At E17.5, though TCF1<sup>+</sup> cells are comparable between controls and E8.5-Derm<sup>Ezh2</sup> mutants, we found an increase of 35% in TCF4<sup>+</sup> cells in the E8.5-Derm<sup>Ezh2</sup> mutant dermis (Fig 3D, E, F). In support of this result, we observed a 11-fold increase in the relative mRNA expression of another reticular progenitor marker, Adiponectin (Fig.3G). However, there was no change in the relative quantities of other PP (Lrig1, Lef1, Prdm1) and RP markers (Dlk1, Col4a1) between controls and E8.5-Derm<sup>Ezh2</sup> mutants in whole skin at E16.5 (Fig.3G). These embryos fail to survive birth for post-natal analysis (data not shown). Taken together, both histomorphometric and q-PCR analyses indicate that Ezh2 promotes differentiation of DF progenitors towards reticular progenitor fate and some markers of RP lineage are targets of dermal PRC2.

Next, we wanted to determine the effect on differentiation of DF progenitors towards hair follicle-forming dermal papilla fibroblasts. During development, the hair follicle-forming fibroblasts make dermal condensates in the dermis which initiate hair follicles (HF) by reciprocally signaling the overlying epidermal keratinocytes to differentiate into placodal cells<sup>5,7,12,53,54</sup>. HF initiation occurs in three waves: primary HF at E14.5, secondary HF at E16.5 and tertiary HF at E18.5<sup>52,55</sup>. First, we assayed for DP differentiation by examining the expression domain of DP markers, Alkaline phosphatase<sup>7</sup> and SOX2<sup>56</sup> which were both comparable between controls and E8.5-Derm<sup>Ezh2</sup> (Fig. S4A-D). Additionally, we surveyed the stages and number of HF in transverse sections across the entire dorsum at the forelimb level. We observed that the primary HF density was comparable between controls and E8.5-Derm<sup>Ezh2</sup>; however, there was a 26% decrease in the secondary HF density at E16.5 (Fig. 3I). By E17.5, the density of primary and secondary hair follicles is comparable between controls and E8.5-Derm<sup>Ezh2</sup> (Fig.3J). Noggin is required for secondary hair follicle initiation<sup>57–59</sup>. We found the relative quantities of Noggin mRNA was 38% lower in E8.5-Derm<sup>Ezh2</sup> (Fig.3K). These results suggest that dermal Ezh2 ablation delays secondary hair follicle initiation possibly by impacting NOGGIN-mediated gene network without affecting differentiation of DF progenitors. Thus, dermal PRC2-EZH2 activity is dispensable for primary hair follicle initiation and is required to regulate the gene network for secondary hair follicle initiation.

**E8.5-Derm<sup>Ezh2</sup> mutants exhibit epidermal hyperplasia**

PRC2 activity is known to regulate various secreted factors crucial for epidermal differentiation<sup>23,24</sup>. We next investigated the effect of dermal Ezh2 deletion on epidermal differentiation. We observed that E8.5-Derm<sup>Ezh2</sup> mice exhibited hyperplastic epidermis throughout the dorsum skin at E16.5 (Fig4 A, B). The epidermal hyperplasia is evident as early as E13.5 (Fig. S5A-C) and besides the dorsum, the hyperplasia exists at other locations of the skin such as head skin and vibrissae skin (Fig. S5D-G). We examined the expression of KERATIN14, KERATIN10, and FILLAGRIN that are respectively expressed in basal, spinous and granular layers of the E16.5 epidermis<sup>60,61</sup>. We observed an expansion in the expression domain of all the three markers and it is more robust in the K10<sup>+</sup> spinous layer (Fig. 4D, E, G-J). This hyperplasia is due to an increase in the number of cells: 37% increase in basal (K14<sup>+</sup>) and 41% increase in supra-basal (K10<sup>+</sup> and FILAGGRIN<sup>+</sup>) layers (Fig.4F, K) and not due to periderm retention, which is known to delay epidermal barrier formation<sup>62,63</sup>. We found relative quantity of the periderm marker, Krtap13, and
barrier acquisition is comparable in control and *E8.5-DermEzh2* skin at E17.5 by qPCR (data not shown, Fig. S6A-D).

We next sought to determine whether epidermal hyperplasia is a result of increased proliferation in *E8.5-DermEzh2*. Epidermal hyperplasia is first observed at E13.5, therefore we analyzed the proliferation index of the surface ectoderm at E10.5 which are the precursors of epidermal basal keratinocytes. Compared to the average of 45.53% EdU+ proliferation index in controls, we found a significant increase at 56.37% in *E8.5-DermEzh2* ectoderm (Fig.4L, M, N). Lastly, we also tested whether accelerated differentiation contributes to epidermal hyperplasia. In controls, FILAGGRIN protein is expressed in the granular layer at E16.5 in the controls (Fig. 4I). However, we found FILAGGRIN protein expression was expressed by E15.5 in *E8.5-DermEzh2* mice (Fig.S6E, F). We identified that hyperplasia is a stage dependent phenotype where initiation of *Ezh2* deletion at E9.5 doesn’t result in hyperplasic epidermis (data not shown). These data together suggest that dermal *Ezh2* ablation leads to elevated keratinocyte promoting factors in the skin that promote their proliferation and differentiation resulting in epidermal hyperplasia (Fig. 4O, P).

**Dermal *Ezh2* regulates cutaneous RA signaling which is sufficient to induce epidermal hyperplasia**

Since dermal *Ezh2* deletion leads to epidermal hyperplasia, we next took a candidate approach to investigate if known signaling factors involved in the regulation of epidermal proliferation and differentiation are dysregulated in *E8.5-DermEzh2*. Administration of RA results in epidermal proliferation and subsequent epidermal thickening in human skin as seen in *E8.5-DermEzh2*. We queried whether RA signaling is dysregulated in *E8.5-DermEzh2* skin. First, we utilized the transgenic RA signaling reporter allele, *RARE-LacZ*. β-gal staining revealed an increase in the *LacZ*+ cells in *E8.5-DermEzh2* dermis at E10.5 (Fig.5A, B). Second, we looked at the expression of an RA target, RAR-γ, and found that there was a clear increase in RAR-γ+ cells in both the epidermis and dermis at E12.5 (Fig.5C, D). Both these data suggest an upregulation of RA signaling in *E8.5-DermEzh2* skin.

Since retinoic acid signaling is elevated in *E8.5-DermEzh2* epidermis at E10.5, we tested the functional significance of this pathway, in causing epidermal hyperplasia, using a pharmacological approach. We administered a single dose of exogenous all-trans-RA (at-RA) orally to pregnant wild-type mice carrying E10.0 embryos, the time-point at which RA signaling is dysregulated in *E8.5-DermEzh2* mutants (Fig. 5E). Compared to the vehicle-treated (DMSO) controls at E18.5, we found a 28.7% increase in epidermal area of at-RA-treated embryos (Fig. 6F, G). Similar to *E8.5-DermEzh2*, at-RA-treated embryos demonstrated expansion of both K10+ spinous and FILAGNRIN+ granular layers of the epidermis at E18.5 (Fig. 5H-I). These data demonstrate that a one-time administration of at-RA at E10.0 is sufficient to cause epidermal hyperplasia. In essence, dermal *Ezh2* ablation leads to upregulation of RA signaling dependent keratinocyte factors which may mediate the epidermal hyperplasia seen in *E8.5-DermEzh2* mutants.

**Antagonizing RA signaling rescues epidermal hyperplasia in *E8.5-DermEzh2* mice**
To test that elevated RA signaling contributes to the epidermal hyperplasia observed in E8.5-\textit{Derm}^{Ezh2} mice, we investigated whether antagonizing RA-signaling is sufficient to rescue epidermal hyperplasia. We orally administered BMS453, a small molecule inhibitor of RARα and RARγ\textsuperscript{16,58} that we validated in previous studies\textsuperscript{29}. At 3.5μg/g body weight dosing regimen of BMS453 (Fig.6A), we rescued the epidermal area by 20.6% as compared to the vehicle-treated (DMSO) E8.5-\textit{Derm}^{Ezh2} (Fig. 6B-F). Thus, the role of dermal Ezh2 is to ensure that RA signaling is carefully regulated to suppress keratinocyte targeted mitogenic factors and regulate normal epidermal proliferation.

In summary, our data suggest a spatio-temporal regulation of RA and Wnt/β-catenin signaling by dermal EZH2 during dermal fibroblast differentiation and epidermal-dermal signaling. We show that ablation of Ezh2 (i) promotes Wnt/β-catenin signaling mediated differentiation of ectopic mesenchymal cells into DF progenitors (ii) promotes DF progenitor differentiation into RPs and (iii) delays secondary hair follicle formation (iv) promotes RA signaling which results in epidermal hyperplasia due to excess proliferation. Further, we rescued the epidermal hyperplasia in Ezh2 mutants by antagonizing RA signaling with BMS453.

**Discussion**

The role of PRC2 in directly regulating key developmental signaling factors and transcription factors is established in embryonic stem cells and tissue-specific stem cells\textsuperscript{65}, but its role in coordinating spatio-temporal cell signaling events within and across tissue-specific progenitors is largely unexplored. Skin development and skin patterning with hair follicles is dependent on the coordination between the stepwise differentiation of dermal fibroblasts concomitant with dermal-epidermal reciprocal signaling. In this study, we examined the developmental role of dermal Ezh2 during dermal fibroblast cell fate selection and reciprocal signaling with the overlying epidermis. Here we report a new action of dermal EZH2 acts as a rheostat of Wnt and RA cell signaling in the dermis. PRC2-EZH2 activity is required for spatially restricting Wnt/β-catenin signaling to reinforce DF specification and prevent lower dermal mesenchyme cells from erroneously adopting a dermal fibroblast fate. Additionally, we uncovered new roles for dermal Ezh2 to non-cell autonomously control epidermal proliferation and differentiation by maintaining critical RA signaling levels. We found that dermal PRC2 activity is a key component of the gene regulatory network of dermal fibroblasts differentiation and dermal-epidermal signaling.

Multiple studies have demonstrated the cell autonomous regulation of PRC2-EZH2 in various cell types. In the craniofacial mesenchyme, EZH2 directly represses anti-osteogenic factors such as \textit{Hox} genes and \textit{Hand2} to allow for differentiation of osteoblasts into mineralized craniofacial bone\textsuperscript{28,30}. Ezh2 deletion in limb mesenchyme causes an increase in cell death and alteration in axis specification factors\textsuperscript{66}. Eed ablation in committed cartilage progenitors, accelerates chondrocyte differentiation and premature ossification leading to a growth defect. Similarly, Ezh2 knockout in specified calvarial bone progenitors causes premature ossification of the suture mesenchyme causing craniosynostosis of the coronal suture\textsuperscript{29,30}. In addition, Eun et al., (2015)\textsuperscript{31} highlights the non-cell autonomous regulation of E(z), a homolog of EZH1/2 in drosophila, where ablation of E(z) in somatic gonad cells leads to somatic cell marker expression in germ cells. Although these studies demonstrated that EZH2 can exhibit cell and non-cell autonomous regulation in different contexts, they do not demonstrate whether and how EZH2 can simultaneously exhibit both during development. In this study, we found that dermal PRC2-EZH2...
cell autonomously regulates differentiation of dermal fibroblast heterogeneity by inhibiting intrinsic effectors of Wnt/β-catenin signaling in the mesenchyme beneath the dermis. Simultaneously, PRC2-EZH2 non-cell autonomously regulates proliferation of epidermal basal keratinocytes by suppressing RA signaling mediated extrinsic factors.

Dermal EZH2 represses Wnt/β-catenin signaling activation in the mesenchymal cells, underlying dermis, during cell fate selection.

Wnt signaling plays a key role in mammalian embryonic dermal cell fate specification and later in differentiation of dermal condensate. Ectoderm Wnts are required for canonical Wnt signaling in mouse dermal fibroblasts precursors, however it is not known how the non-cell autonomous spatial restriction of Wnt signaling is achieved. In this study we found, deletion of dermal Ezh2 causes expansion of Wnt signaling reporter and Wnt responsive-markers that are expressed by lineage-committed dermal fibroblast progenitor cells. However, the ectopic Wnt signaling is not sufficient to increase cell density and proliferation as seen in constitutive Wnt signaling mutants. Previous studies have demonstrated that Wnt/β-catenin signaling is required for dermal fibroblast cell fate. Wnt/β-catenin signaling at E11.5 is necessary and sufficient for Twist2/Dermo1 and Lef1 expression in DF progenitors, respectively. When Ezh2, a component of PRC2 is ablated in pre-adipocytes in vitro and chondrocytes in vivo, Wnts and its targets are ectopically de-repressed resulting in upregulation of Wnt/β-catenin signaling.

Consistent with these studies, we show that dermal-Ezh2 ablation leads to ectopic Wnt/β-catenin signaling at E12.5 which correlates with an expansion of TWIST2+ and LEF1+ domain of DF progenitors. Future studies will focus on rescuing the dermal Ezh2 mutants by restoring varying levels of Wnt signaling and its interaction with RA signaling using pharmacological and genetic approaches.

Both TCF1 and TCF4 are targets of Wnt signaling. It is important to note that these targets are differentially expressed depending on the level of Wnt signaling. TCF1 is a Wnt6 target gene and TCF4 is a Wnt10 target gene. We found that E8.5-DermEzh2 mice have more TCF4+ cells and comparable TCF1+ cells with respect to controls. These data support the inference that a higher number of dermal cells are experiencing low levels of Wnt signaling ectopically. Previous studies have shown upregulation of Wnt signaling by stabilizing β-catenin is sufficient to significantly expand the dermis. However, the dermal thickness of dermal Ezh2 mutants does not change, indicating that the level of upregulation of Wnt signaling seen in the dermal Ezh2 mutants is not sufficient to induce increase in dermal proliferation and thickening. This finding follows the “dimmer switch” model proposed by Nehila et al., (2020) where knocking out epigenetic repressors such as PRC2 does not completely eliminate the target activators/repressors, instead it serves as a rheostat to modulate expression level of activators/repressors.

Loss of dermal Ezh2 promotes upregulation of reticular dermal markers and delays secondary hair follicle initiation.

Dermal fibroblast progenitors differentiate into PPs in the upper dermis, RPs in the lower dermis, and DC under hair follicle placodes. Driskell et al., (2012) showed that dermal fibroblast progenitors start to express distinct lineage markers in the dermis as early as E14.5. The markers of both PPs, RPs, and DC lineages are regulated by Wnt signaling as shown in published RNA sequencing dataset. It is unclear from the literature on dermal Wnt signaling knockouts and constitutive Wnt signaling mutants when and how much Wnt signaling is required for differentiation of these dermal lineages and if epigenetic regulators control levels of dermal Wnt.
signaling. The level of Wnt signaling elevation seen in Ezh2 knockout mice between E16.5 and E17.5 sufficiently induced changes in reticular dermal markers without altering papillary dermal markers. This can be explained in two possible ways: (i) that the threshold for modulating Wnt signaling is lower to induce changes in reticular dermal differentiation lineage markers than other lineages and/or (ii) Wnt signaling mediated PRC2 regulation of dermal markers at E16.5 is spatially restricted just to the reticular dermis while the papillary dermal marker regulation is independent of PRC2.

Ablation of β-catenin in DF precursors leads to a complete absence of DF progenitors and DP cells and stabilization of β-catenin leads to ectopic DP formation resulting in an increase in the number of hair follicles. In contrast to these studies, we found a delayed initiation of secondary hair follicles in dermal Ezh2 mutants. We show that the expression of DP markers, ALP and SOX2, are comparable between controls and E8.5-DermEzh2. So, two possible explanations of this effect are (i) that Ezh2 negatively impacts the gene regulatory network of secondary DP initiation, but not primary DP initiation or (ii) that dermal Ezh2 non-cell autonomously suppresses epidermal keratinocyte differentiation towards secondary follicular cell fate. These explanations are consistent with previous evidence suggesting that morphogenesis of the primary and secondary hair follicles is controlled by different mechanisms.

Loss of dermal Ezh2 induces ectopic proliferation and differentiation of epidermal keratinocytes in a non-cell autonomous manner

A unique phenotype of the dermal Ezh2 mutant is the epidermal hyperplasia due to an increase in proliferation and accelerated differentiation of basal keratinocytes in the epidermis. Our data strongly suggest that extrinsic factors from the dermis play a causal role in epidermal hyperplasia. Addition ally, we found that exogenous at-RA exposure in WT embryos in vivo induced epidermal hyperplasia and RA signaling inhibitor treatment to E8.5-DermEzh2 mice rescued the hyperplasia. The association of embryonic murine epidermal hyperplasia and RA signaling was present in Cybp26b1−/− mutant and dermal Cyb26b1β/del, a negative regulator of RA signaling.

There are several dermal signaling factors controlled by Ezh2 during skin development that can regulate epidermal proliferation and differentiation. Among these, we propose two plausible factors that may be involved in epidermal signaling thus causing RA-mediated hyperplasia. (i) Given that epidermal metabolites are solely transferred from the dermis, elevated transient RA signaling can result from the ectopic transfer of RA metabolite from dermis to the epidermis thus leading to excessive proliferation and accelerated differentiation. (ii) PRC2 is known to epigenetically silence loci of Wnt ligands in mesenchymal derivatives, pre-adipocytes and chondrocytes. (iii) Wnt and RA signaling crosstalk in many contexts. Thus, it is possible that Ezh2 ablation derepresses Wnts in the dermal mesenchyme and promotes RA-signaling effectors that further mediate keratinocyte proliferation and accelerated differentiation. Future studies will investigate the identity of Ezh2 regulated RA-sensitive mediators and understanding the mechanism of BMS453 mediate rescue of epidermal hyperplasia.

In summary, our data supports that epigenetic regulators such as PRC2-EZH2 can simultaneously regulate intrinsic and extrinsic factors through different signaling pathways. Precisely, dermal Ezh2 regulates intrinsic factors such as TWIST2 and LEF1 via Wnt/β-catenin signaling to control DF progenitor differentiation. Aberrant activation of Wnt/β-catenin signaling...
occurs in dermal fibrosis and internal organ fibrosis\textsuperscript{78,79}. Thus, elevating PRC2 activity to repress Wnt signaling may be a new therapeutic approach to abrogate skin and organ fibrosis. Further, dermal Ezh2 directed down regulation of RA signaling mediated extrinsic factors is critical for the timely regulation of epidermal proliferation and differentiation. This approach can be employed to treat elevated RA signaling seen in psoriatic lesions\textsuperscript{80–82}. Our data are consistent that PRC2-EZH2 is a new “dimmer switch” or rheostat. It modulates levels or spatial restriction of Wnt/β-catenin and RA signaling \textit{in vivo} to impact cell differentiation and rate of proliferation in cell autonomous and non-autonomous ways.

\textbf{Acknowledgements:}

Thanks to previous and current members of the Atit Lab for their input and feedback. We thank Gregg DiNuoscio and Vidhi Mendpara for genotyping animals. We thank Dr. Elena Ezhkhova, Dr. Peggy Myung, Dr. Martin Basch, and Dr. Claudia Mizutani for critical feedback. We thank Brian Zhang, Celine Opdycke and Charlotte Lo for help with manual and automated counting. We thank the SOM Light Microscopy Core Facility and the CWRU bio[box] shared instrumentation facility.

\textbf{Author Contributions}

V.T. and R.P.A. conceived experiment, analyzed and interpreted data. V.T., T.N., J.F. carried out the experiments, and V.T. generated the figures.

\textbf{Conflict of Interest}

The authors declare that they have no competing interests.

\textbf{Funding:} This work was supported by NIH-NIDCR: R01-01870 (RA) and the NIH Grant S10-OD016164 (CWRU SOM Light Microscopy Core Facility).

\textbf{References:}


Daudet, N., Ariza-McNaughton, L. & Lewis, J. Notch signalling is needed to maintain, but not to initiate, the formation of prosensory patches in the chick inner ear. *Development* (2007). doi:10.1242/dev.001842


Driskell, R. R., Jahoda, C. A. B., Chuong, C. M., Watt, F. M. & Horsley, V. Defining


**Figure Legends:**

**Figure1: Ezh2 is efficiently deleted in the dermal mesenchyme by PDGFRαCreER:** Schematic depicting the skin development program (A). Indirect immunofluorescence of...
H3K27me3 with DAPI counterstain at various stages of dermal development (B). Schematic illustration of tamoxifen gavage regimen (C) utilized in the study. β-galactosidase staining (D, E) depicting the region of Cre-ER recombinase of R26R expression. Indirect immunofluorescence of H3K27me3 with DAPI counterstain at E10.5 (F, G) and its quantification (H). Solid line demarcates the epidermis from dermis and dashed line demarcates the lower limit of the dermis. Scale bar=100 microns in B and 50 microns in D-G.

**Figure 2:** *Ezh2 restricts the specification of Wnt/ β-Catenin Signaling mediated DF progenitors to the dermis:* Schematic illustration of the temporal window (A’) and region of interest (A’’). Indirect immunofluorescence with DAPI counterstain showing the expression of mesenchymal marker, PDGFRα (B, C), and dermal fibroblast progenitor markers TWIST2 (E, F), and LEF1 (H, I). Axin2-LacZ (β-galactosidase) staining (K, L) at E12.5. Schematic illustration of binning of dermis and dorsal mesenchyme employed to quantify cells (D). Quantification of TWIST2+ (G), LEF1+ (J), and β-galactosidase+ (M) cells in both controls and mutants. A summary schematic depicting the extent of Wnt/ β-Catenin signaling domain in control and expansion in theE8.5-Derm*Ezh2* mice (N). Solid line demarcates the epidermis from dermis and dashed line demarcates the lower limit of the dermis. Scale bar=100 microns in B, C, H, I, K, L and 50 microns in E and F.

**Figure 3:** *Dermal Ezh2 ablation promotes DF progenitor differentiation towards reticular progenitors and delays secondary hair follicle initiation in E8.5-Derm*Ezh2*: Immunohistochemistry (A, B, C, D) of a PP marker, TCF1 (A, B), and an RP marker, TCF4 (D, E), with hematoxylin counterstain. Quantification of TCF1+ (C) and TCF4+ (F) cells in the dermis. The relative quantity of papillary (G) and reticular (H) progenitor markers in E16.5 whole skin between controls and E8.5-Derm*Ezh2*. Hair follicle density at E16.5 (I) and E17.5 (J). The relative quantity of secondary HF initiation gene, Noggin (K). Solid line demarcates the epidermis from dermis. Scale bar=100 microns in A, B, D and E.

**Figure 4:** *E8.5-Derm*Ezh2* mice exhibit epidermal hyperplasia as a result of ectopic proliferation:* Hematoxylin and eosin staining of dorsal body (A, B) Schematic illustration of the regions of interest (C). Indirect immunofluorescence with DAPI counterstain at E16.5 (D, E, G-H, I, J) with markers of basal keratinocytes (D, E), spinous keratinocytes (G, H) and granular keratinocytes (I, J). Percentage of basal (F) and suprabasal cells (K) in both controls and mutants. Edu staining with DAPI counterstain at E10.5 (L, M). Proliferation index of EdU+ basal keratinocytes in controls and mutants (N). A summary schematic depicting the effect of dermal Ezh2 deletion on the epidermis (O). Schematic with the proposed model by which dermal *Ezh2*...
Ablation leads to epidermal hyperplasia. Solid line demarcates the epidermis from dermis and dashed line demarcates the lower limit of the dermis. Scale Bar= 50 microns.

**Figure 5: Retinoic acid is regulated by Ezh2 and is sufficient to induce epidermal hyperplasia:** β-galactosidase staining of RARE-LacZ (A, B) at E10.5. Indirect immunofluorescence with DAPI counterstain showing the expression of RA signaling target gene, RARγ (C, D) at E12.5. Schematic illustration of Retinoic Acid (E) gavage regimen. Hematoxylin and eosin staining of dorsal skin (F, G) showing the histology of the epidermis. Indirect immunofluorescence of FILAGGRIN (H, I) and KERATIN10 (J, K) with DAPI counterstain at E18.5. Comparison of epidermal area between controls and mutants in Retinoic acid treated MICE (L). A summary schematic depicting the epidermal hyperplasia phenotype (M) and the relationship between EZH2 and retinoic acid signaling (N). Solid line demarcates the epidermis from dermis and dashed line demarcates the lower limit of the dermis. Scale Bar= 50 microns.

**Figure 6: Pharmacological inhibition of Retinoic acid signaling rescues the epidermal hyperplasia in E8.5-DermEzh2:** Schematic illustration BMS453 (A) gavage regimens. Hematoxylin and eosin staining of dorsal skin (B, C, D) showing the histology of the epidermis. Comparison of epidermal area between Controls, E8.5-DermEzh2 and BMS treated-E8.5-DermEzh2 mice (E). A summary schematic depicting the rescue of epidermal hyperplasia (F). The proposed model by which BMS453 is rescuing the hyperplasia in E8.5-DermEzh2 (G). Solid line demarcates the epidermal from the dermis. Scale Bar= 50 microns.

**Supplementary Figures**

**Figure S1: PDGFRαCreER efficiently deletes mesenchymal Ezh2:** The relative quantity of Ezh2 (A), in E10.5 flow sorted dorsal mesenchyme isolated from conditional heterozygous E8.5-DermEzh2flox/+ controls and E8.5-DermEzh2. Indirect immunofluorescence of H3K27me3 with DAPI counterstain at E13.5 (B, C). Solid line demarcates the epidermis from dermis and dashed line demarcates the lower limit of the dermis. Scale Bar= 50 microns in B and C.

**Figure S2: Dermal density and thickness are comparable between controls and E8.5-DermEzh2 despite the persistence of Wnt signaling upregulation till E13.5.** Dermal proliferation index at E10.5 (A) and cell density (B) at E12.5. Masson’s Trichrome staining (C, D) at E17.5 showing the thickness of the dermis and its quantification (E). The relative quantity of Wnt signaling target genes, Lef1 (F) and Axin2 (G) in E13.5 whole skin between controls and E8.5-DermEzh2. Scale Bar= 200 microns in C and D.

**Figure S3: The PP marker, LRIG1, and the RP marker, DLK1, are comparable between controls and E8.5-DermEzh2 mutants:** Indirect immunofluorescence with DAPI counterstain (A-
D) showing papillary progenitor marker, LRIG1 (A, B), and reticular progenitor marker, DLK1 (C, D). Schematic illustration of binning of dermis employed to quantify LRIG1+/DLK1+ cells (E). Corrected fluorescence of LRIG1 (F) and DLK1 (G). Solid line demarcates the epidermis from dermis and dashed line demarcates the lower limit of the dermis. Scale Bar= 100 microns in A-D.

FigureS4: The dermal papilla marker expression is comparable between the controls and E8.5-DermEzh2 mice at E16.5. Alkaline phosphatase, a dermal papilla marker, staining at E16.5 (A, B). Indirect immunofluorescence of dermal papilla marker, Sox2, with DAPI counterstain at E16.5 (C, D). Scale bar = 50 microns in A-D.

FigureS5: Epidermal hyperplasia in E8.5-DermEzh2 mice is evident at various locations and from E13.5 onwards: Hematoxylin and eosin staining of dorsal skin (A, B, D-G) showing the histology of the epidermis at E13.5 (A, B) and E16.5 (D-G). Quantification of the number of epidermal keratinocytes at E13.5 between controls and E8.5-DermEzh2 (C). Solid line demarcates the epidermis from dermis and dashed line demarcates the lower limit of the dermis. Scale Bar= 100 microns in A, B, D-G.

FigureS6: E8.5-DermEzh2 mice have intact barrier but exhibits accelerated differentiation: Whole mount toluidine blue O staining at E16 (A, B) and E17.5 (C, D). Indirect immunofluorescence of FILAGGRIN (E, F) with DAPI counterstain at E15.5. Solid line demarcates the epidermis from the dermis. Scale bar = 50 microns in A-D.

FigureS7: PRC2 components are not regulated by retinoic acid signaling. The relative quantity of Cyp26b1 (A), a target of RA signaling, and PRC2 components (B-D) in RA treated wild-type skin in comparison to vehicle control treated embryos at E10.5.
Figure 1

Control

E8.5-Derm<sup>fl/fl</sup>; R2<sup>6R/</sup> × PdgfraCreER<sup>T2</sup>; Ezh2<sup>fl/fl</sup>

Tamoxifen oral gavage 25 μg/g of bw

**A** E9.5 - E11.5
Surface ectoderm (pre-epidermal specification)
Dermal fibroblast migration sub-ectodermally

E11.5 - E13.5
Epidermal specification
Dermal fibroblast specification

E14.5 - P2
Dermal fibroblast differentiation
Epidermal differentiation & stratification
Hair follicle morphogenesis

**B**

**C**

E8.5-Derm<sup>fl/fl</sup>; R2<sup>6R/</sup> × PdgfraCreER<sup>T2</sup>; Ezh2<sup>fl/fl</sup>

Tamoxifen oral gavage 25 μg/g of bw

**D**

**E**

**F**

**G**

**H**

Thulabandu et al.,
Figure 1

---

*Note: The figure includes a diagram illustrating the temporal and cellular changes during embryonic development, focusing on epidermal and dermal lineages. Various markers and events are highlighted, including the expression of α-H3K27me3 and Ezh2. The figure also shows the impact of Tamoxifen treatment on E8.5-Derm<sup>fl/fl</sup>; R2<sup>6R/</sup> and PdgfraCreER<sup>T2</sup>; Ezh2<sup>fl/fl</sup> genotypes. Graphs indicate changes in H3K27me3+ cells between control and E8.5-Derm<sup>fl/fl</sup> conditions.*
Dermal fibroblast specification

**A**

E9.5-E13.5

Dermal Fibroblast Precursors

En1+

PDGFRα+

E11.5-E13.5

Dermal Fibroblast Progenitors

PDGFRα+

Twist2+

Lef1+

**A'**

Dorsal

Body

**A''**

**B**

EPIDERMIS

DERMIS

**D**

**E**

α-PDGFRα

**E12.5**

**F**

α-Twist2

**E12.5**

**G**

1st & 2nd bins

3rd, 4th & 5th bins

**H**

α-Lef1

**E12.5**

**I**

Axin2-LacZ

**E12.5**

**J**

1st & 2nd bins

3rd, 4th & 5th bins

**K**

Control

E8.5-DermEzh2

**M**

1st & 2nd bins

3rd, 4th & 5th bins

**N**

**CONTROL**

**E8.5-DermEzh2**

Epidermis

Dermis

Mesenchyme

Ezh2

Wnt signaling

Mesenchymal cell

Wnt signaling dermal fibroblast progenitors

Thulabandu et al., Figure 2
Dermal fibroblast differentiation into papillary and reticular progenitors

**A** EPIDERMIS

**D** E17.5

**α-TCF1**

**G** Papillary dermal markers at E16.5

Lrig1  n.s.  Lef1  n.s.  Prdm1  n.s.

**H** Reticular dermal markers at E16.5

Dlk1  n.s.  Col4A1  n.s.  Adiponectin

**Formed of hair follicles**

**I** HF density at E16.5

Primary hair follicles  n.s.  Secondary hair follicles

**J** HF density at E17.5

Primary hair follicles  n.s.  Secondary hair follicles

**K** Noggin expression at E16.5

Figure 3
Thulabandu et al.,
Figure 4  Thulabandu et al.,
Figure 6
Thulabandu et al.,
Figure S1: PDGFRαCre efficiently deletes mesenchymal Ezh2. The relative quantity of Ezh2 (A), in E10.5 flow sorted dorsal mesenchyme using conditional heterozygous E8.5-DermEzh2<sup>flox/+</sup> controls and E8.5-DermEzh2<sup>−/−</sup>. Indirect immunofluorescence of H3K27me3 with DAPI counterstain at E13.5 (H,I) showing the efficiency and mosaicing of the mouse model utilized in the study.
**Dermal fibroblast precursors**

A. Percentage of EdG1+ cells

B. Cell density

**Papillary and reticular progenitor stage**

C. Control

D. E8.5-Derm$^{Ezh2}$

E. Dermal thickness (μm)

**Dermal fibroblast progenitors**

F. Lef1

G. Axin2

Thulabandu et al.,
Supplementary Figure 2
Figure S4: The dermal papilla marker expression is comparable between the controls and E8.5-DermEzh2 mice at E16.5. Alkaline phosphatase, a dermal papilla marker, staining at E16.5 (A, B). Indirect immunofluorescence of dermal papilla marker, Sox2, with DAPI counterstain at E16.5 (C, D).

Thulabandu et al., Supplementary Figure 3
<table>
<thead>
<tr>
<th>Control</th>
<th>E8.5-DermEzh2</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Alkaline Phosphatase stain" /></td>
<td><img src="image2.png" alt="Alkaline Phosphatase stain" /></td>
</tr>
<tr>
<td><img src="image3.png" alt="α-Sox2" /></td>
<td><img src="image4.png" alt="α-Sox2" /></td>
</tr>
</tbody>
</table>

Thulabandu et al.,
Supplementary Figure 4
Thulabandu et al.,
Supplementary Figure 5
Thulabandu et al.,
Supplementary Figure 6
Thulabandu et al.,
Supplementary Figure 7